Filter By Category
Archives
Share on -
BIVALIRUDIN
Generic Name: BIVALIRUDIN
ABSTRACT -
Bivalirudin is a peptide-based API described as a Synthetic peptide anticoagulant. Peptide sequence, stereochemistry, salt form, and labeling/conjugation details should be controlled in the product specification.
Verified structural identifier information used for this sheet includes molecular formula C98H138N24O33, PubChem CID 16129704. For regulatory filing, confirm final salt form, stereochemistry, hydration state, and manufacturer-specific specification before submission.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Dose, route, and frequency depend on indication, formulation, and protocol.
- Use only with appropriate clinical monitoring.
- Do not administer outside authorized labeling or trial guidance.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Bleeding, bruising, injection-site reactions, or procedural complications depending on indication
- Nausea, headache, hypotension, or hypersensitivity symptoms
- Laboratory abnormalities related to anticoagulant or peptide activity when applicable
- Antibody formation or immune reaction is possible with some peptide products
ALLERGIC REACTIONS -
Hypersensitivity to Bivalirudin or related compounds/products may occur. Symptoms may include:
- Immediate urticaria or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing or breathing difficulty
- Dizziness, collapse, or anaphylaxis
Important: Patients who develop an allergic reaction to Bivalirudin should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Bivalirudin may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Concomitant medicines with overlapping pharmacology may increase adverse effects.
- Renal/hepatic impairment or procedure-related therapies may require special review.
- Patients should inform healthcare providers about all medicines and supplements they use.
PREAUTONS–
- Confirm identity, formulation, strength, route, and intended indication before use.
- Review allergy history and prior serious adverse reactions.
- Monitor according to the product specification and clinical protocol.
- Pregnancy and lactation safety may be limited or unknown.
WARNINGS –
- This document is for structured API information only and is not a prescribing guide.
- Use only according to approved labeling, clinical-trial protocol, or qualified specialist instruction.
- Stop use and seek urgent medical care for severe allergic reaction, breathing difficulty, collapse, or serious unexpected symptoms.
- Keep out of reach of children.
Share on -
. Developed by